MFC Co., Ltd. Logo

MFC Co., Ltd.

A GMP-certified CDMO/CMO developing and manufacturing APIs for the global pharma sector.

432980 | KO

Overview

Corporate Details

ISIN(s):
KR7432980001
LEI:
Country:
South Korea
Address:
경기도 화성시 마도면 청원산단7길 35(청원리 1453), 화성시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Established in 2008, MFC Co., Ltd. is a pharmaceutical company specializing in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and key intermediates. The company offers Contract Development and Manufacturing Organization (CDMO) and Contract Manufacturing Organization (CMO) services tailored to the global pharmaceutical sector. As a GMP-certified manufacturer, MFC focuses on producing high-quality raw medicines and new APIs, aiming to become a global leader in pharmaceutical development and technology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-03 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 82.4 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.0 MB
2025-06-16 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 780.1 KB
2025-04-04 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-03-31 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 11.0 KB
2025-03-28 00:00
Board/Management Information
대표이사변경
Korean 12.3 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 28.6 KB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 19.1 KB
2025-03-20 00:00
Annual / Quarterly Financial Statement
사업보고서 (2024.12)
Korean 423.5 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 85.2 KB
2025-03-07 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-03-06 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 16.4 KB
2025-03-06 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 5.0 KB
2025-02-28 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 66.5 KB

Automate Your Workflow. Get a real-time feed of all MFC Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MFC Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MFC Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LENZ Therapeutics, Inc. Logo
Develops a prescription eye drop for presbyopia, the age-related loss of near vision.
United States of America
LENZ
Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America
LEXX
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America
LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America
LXRX
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America
LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America
LIMN
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel
LCTX
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden
LPGO
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden
LIPUM

Talk to a Data Expert

Have a question? We'll get back to you promptly.